EGFR and non-small cell lung carcinoma: It known to all TKIs inhibit the phosphorylation of EGFR and the activation of the downstream pathway leads to cytotoxicity in EGFR sensitive mutation NSCLC cells; Zhang et al. reported that EGFR stabilizes SCD1 through Y55 phosphorylation and up-regulating MUFA synthesis to promote lung cancer growth [16].